Ishikawa T, Uemura Y, Seki H, Kitada M, et al. Real-world data for a CDK4/6 inhibitor, palbociclib, as 1st- or 2nd-line therapy in HR+/HER2- metastatic breast cancer: a multicenter prospective cohort study. Breast Cancer Res 2026 May 29. doi: 10.1186/s13058-026-02313.
PMID: 42216212